Bone-marrow focused Imago BioSciences scores $40M in Omega-led round
Roughly four and half years after securing $26.5 million in a Clarus Ventures-led Series A, San Francisco biotech Imago BioSciences has another $40 million in the bank to develop its bone marrow-focused therapy, courtesy a financing round led by Omega Funds.
The privately-held drug developer is targeting the management of proliferative diseases of the bone marrow — including acute myeloid leukemia (AML), myelodysplastic syndrome, polycythemia vera, myelofibrosis and essential thrombocythemia — that trigger unbridled bone marrow cell growth, driven by genetic mutations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.